Constipation • Intestinal transit • Anti-inflammatory • Reduction of gastro-intestinal discomfort • Inhibition of pathogenic E. coli • Restoration of a better dietary ω-6/ω-3 balance • Conjugated linoleic acids (CLA) production • Prospective use in the treatment of obesity • Cystitis • Inhibition of E. coli • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence
Bifidobacterium breve – BR03 (DSM 16604)
Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly CIBUS, 2005; 1(1):23-30.
Del Piano M. et al. Evaluation of the intestinal colonization by microencapsulated probiotic bacteria in comparison with the same uncoated strains. J Clin Gastroenterol. 2010; 44 Suppl 1:S42-6.
Internal data available upon request at Probiotical.
Nicola S. et al. Interaction between probiotics and human immune cells: the prospective anti-inflammatory activity of Bifidobacterium breve BR03. AgroFOOD, 2010; 21(2):S44-47.
Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice. J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008. (DSM 20074 was re-deposited as 22106).
Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains (LP01, LP02, LR04, LR06, LPS01, LDD01, BR03, B632). J Clin Gastroenterol. 2012; 46 Suppl:S29-32.
Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.